Clover posts strong RSV re-vaccination data in head-to-head trial with GSK

Clover Biopharmaceuticals Ltd. ( (HK:2197) ) has provided an update.

Clover Biopharmaceuticals reported additional positive U.S. Phase I data for its RSV PreF vaccine candidate SCB-1019 in older adults previously vaccinated with GSK’s AREXVY. In a head-to-head re-vaccination study, SCB-1019 showed roughly 60-80% higher neutralizing antibody titers against RSV-A and RSV-B than homologous AREXVY re-vaccination and restored antibody levels to above the peak seen after an initial AREXVY dose.

The data also highlighted that AREXVY re-vaccination generated a strong off-target antibody response to its T4-foldon tag, while Clover’s candidate did not show this issue, underscoring a potential safety and specificity advantage. With tens of millions of older adults already exposed to protein-based RSV vaccines and waning efficacy limiting current re-vaccination policies, Clover’s results support the potential of its RSV+hMPV±PIV3 combination vaccines, now in Phase II trials, to restore and broaden protection in this large, underserved population.

The most recent analyst rating on (HK:2197) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Clover Biopharmaceuticals Ltd. stock, see the HK:2197 Stock Forecast page.

More about Clover Biopharmaceuticals Ltd.

Clover Biopharmaceuticals Ltd. is a China-based biotechnology company focused on developing novel vaccines, including protein-based candidates targeting respiratory viruses. Its pipeline includes an RSV PreF vaccine and combination vaccines aimed at protecting older adults against RSV, human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3), positioning the group in the competitive respiratory vaccine market.

Average Trading Volume: 3,917,451

Technical Sentiment Signal: Buy

Current Market Cap: HK$2.87B

See more insights into 2197 stock on TipRanks’ Stock Analysis page.